Corcept Therapeutics Incorporated (LON:0I3Q)
London · Delayed Price · Currency is GBP · Price in USD | Market Cap | 4.07B -29.8% |
| Revenue (ttm) | 582.44M +12.2% |
| Net Income | 35.35M -64.7% |
| EPS | 0.30 -64.8% |
| Shares Out | n/a |
| PE Ratio | 115.03 |
| Forward PE | 54.87 |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 1,671 |
| Average Volume | 656 |
| Open | 51.18 |
| Previous Close | 51.00 |
| Day's Range | 51.18 - 55.35 |
| 52-Week Range | 28.67 - 91.00 |
| Beta | 0.36 |
| RSI | 72.61 |
| Earnings Date | Apr 30, 2026 |
About Corcept Therapeutics
Corcept Therapeutics Incorporated, a biopharmaceutical company, engages in the discovery and development of medications to treat severe endocrinologic, oncologic, metabolic, and neurologic disorders in the United States. The company offers Korlym, an oral medication for the treatment of hyperglycemia secondary to hypercortisolism in adult patients with endogenous Cushing’s syndrome who have type 2 diabetes mellitus or glucose intolerance and have failed surgery or are not candidates for surgery. It also develops relacorilant, a selective cortis... [Read more]
Financial Performance
In 2025, Corcept Therapeutics's revenue was $761.41 million, an increase of 12.79% compared to the previous year's $675.04 million. Earnings were $98.17 million, a decrease of -29.74%.
Financial numbers in USD Financial StatementsNews
Corcept Therapeutics upgraded to Buy from Neutral at UBS
UBS upgraded Corcept Therapeutics (CORT) to Buy from Neutral with a price target of $72, up from $44. The recent approval of Lifyorli in ovarian cancer is expected to drive…
Corcept Therapeutics upgraded to Buy from Neutral at UBS
UBS upgraded Corcept Therapeutics (CORT) to Buy from Neutral with a $72 price target
Corcept Therapeutics price target raised to $75 from $60 at H.C. Wainwright
H.C. Wainwright raised the firm’s price target on Corcept Therapeutics (CORT) to $75 from $60 and keeps a Buy rating on the shares. The firm says Lifyorli and Korlym strength…
Corcept Therapeutics price target raised to $88 from $73 at Piper Sandler
Piper Sandler raised the firm’s price target on Corcept Therapeutics (CORT) to $88 from $73 and keeps an Overweight rating on the shares following quarterly results. The firm says it…
Corcept Therapeutics announced 2-year OS data from Phase 2 dazucorilant study
Corcept Therapeutics (CORT) “announced two-year overall survival data from the Phase 2 DAZALS study of its proprietary, selective cortisol modulator dazucorilant in patients with amyotrophic lateral s...
Corcept Therapeutics Earnings Call Transcript: Q1 2026
Q1 2026 revenue grew 4.9% year-over-year to $164.9M, but net loss reached $31.8M due to launch costs. Lifyorli’s early FDA approval and rapid adoption, plus strong endocrinology growth, led to raised 2026 guidance of $950M–$1.05B.
Corcept Therapeutics reports Q1 EPS (30c), consensus (14c)
Reports Q1 revenue $164.9M, consensus $186.6M. “This quarter’s results include a significant milestone: With the FDA’s approval of Lifyorli (relacorilant) to treat women with platinum-resistant ovaria...
Corcept Therapeutics raises FY26 revenue view to $950M-$1.05B, consensus $933.2M
16:27 EDT Corcept Therapeutics (CORT) raises FY26 revenue view to $950M-$1.05B, consensus $933.2M
Corcept Phase 2 Study of Dazucorilant Demonstrates Two-Year Overall Survival Benefit in Patients with Amyotrophic Lateral Sclerosis
REDWOOD CITY, Calif.--(BUSINESS WIRE)--Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of medications to treat severe endocrinolog...
Corcept Therapeutics Announces First Quarter Financial Results and Provides Corporate Update
REDWOOD CITY, Calif.--(BUSINESS WIRE)--Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of medications to treat severe endocrinolog...
Corcept Therapeutics to Announce First Quarter Financial Results, Provide Corporate Update and Host Conference Call
REDWOOD CITY, Calif.--(BUSINESS WIRE)--Corcept Therapeutics Incorporated (NASDAQ: CORT) today announced it will report first quarter financial results and provide a corporate update on April 30, 2026....
Corcept to Present New Data from Pivotal Phase 3 ROSELLA Trial of Lifyorli™ (Relacorilant) in Patients with Platinum-Resistant Ovarian Cancer at ASCO 2026
REDWOOD CITY, Calif.--(BUSINESS WIRE)--Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of medications to treat severe endocrinolog...
Corcept Therapeutics presents final overall survival data from ROSELLA trial
Corcept Therapeutics (CORT) presented final overall survival data from its pivotal Phase 3 ROSELLA trial of Lifyorli combined with the chemotherapeutic agent nab-paclitaxel in patients with platinum-r...
Corcept Presents Complete Data from Pivotal ROSELLA Trial in SGO Late-Breaker with Simultaneous Publication in The Lancet: Lifyorli™ (Relacorilant) Plus Nab-Paclitaxel Improves Overall Survival in Patients with Platinum-Resistant Ovarian Cancer
REDWOOD CITY, Calif.--(BUSINESS WIRE)--Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of medications to treat severe endocrinolog...
Shareholders Sue Corcept Therapeutics Over Cushing’s Syndrome Drug Claims
A class action lawsuit was filed against Corcept Therapeutics ($CORT) on February 20, 2026. Plaintiffs -shareholders- in the federal securities class action allege that they acquired Corcept stock at ...
Corcept Therapeutics presents data from Momentum trial at ACC 2026
Corcept Therapeutics (CORT) presented late-breaking data from its Momentum trial examining the prevalence of endogenous hypercortisolism in patients with resistant hypertension at the 2026 American Co...
Corcept Presents Data from MOMENTUM Trial at American College of Cardiology Annual Scientific Session
REDWOOD CITY, Calif.--(BUSINESS WIRE)--Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of medications to treat severe endocrinolog...
Corcept Therapeutics upgraded to Peer Perform from Underperform at Wolfe Research
Wolfe Research analyst Kalpit Patel upgraded Corcept Therapeutics (CORT) to Peer Perform from Underperform with no price target after the company received approval for relacorilant with nab-paclitaxel...
Corcept Therapeutics price target raised to $110 from $100 at Canaccord
Canaccord raised the firm’s price target on Corcept Therapeutics (CORT) to $110 from $100 and keeps a Buy rating on the shares. The firm noted the FDA posted on its…
Corcept Therapeutics price target raised to $110 from $100 at Canaccord
Canaccord analyst Edward Nash raised the firm’s price target on Corcept Therapeutics (CORT) to $110 from $100 and keeps a Buy rating on the shares.
Corcept Therapeutics shares surge as lead drug gets FDA nod for ovarian cancer
Corcept Therapeutics shares jumped more than 32% to nearly a two-month high on Wednesday after the U.S. health regulator approved its lead drug for treating an aggressive form of ovarian cancer that...
Corcept confirms FDA approves Lifyorli for platinum-resistant ovarian cancer
Corcept Therapeutics (CORT) announced that the U.S. Food and Drug Administration has approved Lifyorli in combination with nab-paclitaxel for the treatment of adults with platinum-resistant epithelial...
FDA Approves Corcept's Selective Glucocorticoid Receptor Antagonist Lifyorli™ (relacorilant) Plus Nab-Paclitaxel for Treatment of Patients with Platinum-Resistant Ovarian Cancer
REDWOOD CITY, Calif.--(BUSINESS WIRE)--Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of medications to treat severe endocrinolog...
Corcept Rockets 48% after FDA Lifyorli Approval — What Does This Mean for CORT Stock?
Shares in biopharma company Corcept Therapeutics ($CORT) climbed as high as 48% to $48.35 following U.S. approval of Lifyorli for treating certain ovarian-type cancers. H.C. Wainwright believes the mo...
Corcept Therapeutics price target lowered to $60 from $67 at H.C. Wainwright
H.C. Wainwright lowered the firm’s price target on Corcept Therapeutics (CORT) to $60 from $67 and keeps a Buy rating on the shares. FDA approval of Lifyorli came nearly four…